--- title: "GSK (LON:GSK) Insider Purchases £130.62 in Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/286511281.md" description: "GSK plc insider Julie Brown purchased 7 shares of the company's stock on May 12th for a total of £130.62 at an average price of GBX 1,866 per share. This follows her earlier acquisition of 5 shares at GBX 2,171 each on April 13th. GSK's current stock price is GBX 1,872.50, with a market cap of £74.75 billion and a P/E ratio of 13.18." datetime: "2026-05-15T05:22:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286511281.md) - [en](https://longbridge.com/en/news/286511281.md) - [zh-HK](https://longbridge.com/zh-HK/news/286511281.md) --- # GSK (LON:GSK) Insider Purchases £130.62 in Stock GSK plc (LON:GSK - Get Free Report) insider Julie Brown acquired 7 shares of the business's stock in a transaction dated Tuesday, May 12th. The shares were bought at an average price of GBX 1,866 per share, for a total transaction of £130.62. - Akebia Therapeutics Surges on FDA Approval for Anemia Treatment Julie Brown also recently made the following trade(s): - On Monday, April 13th, Julie Brown acquired 5 shares of GSK stock. The shares were bought at an average price of GBX 2,171 per share, for a total transaction of £108.55. ## GSK Price Performance Shares of LON GSK opened at GBX 1,872.50 on Friday. The business's 50 day moving average price is GBX 2,032.33 and its 200 day moving average price is GBX 1,940.50. The firm has a market cap of £74.75 billion, a P/E ratio of 13.18, a P/E/G ratio of 1.24 and a beta of 0.30. GSK plc has a 52 week low of GBX 1,288.61 and a 52 week high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. - ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. The firm had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. On average, sell-side analysts expect that GSK plc will post 175.980975 earnings per share for the current year. ## Wall Street Analyst Weigh In * * * * * * A number of brokerages have recently issued reports on GSK. UBS Group reiterated a "neutral" rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Berenberg Bank reaffirmed a "hold" rating and issued a GBX 2,000 target price on shares of GSK in a research note on Thursday, March 26th. Jefferies Financial Group reissued a "buy" rating and set a GBX 2,500 price objective on shares of GSK in a research report on Tuesday, April 14th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a GBX 1,900 price objective on shares of GSK in a research report on Wednesday, May 6th. Finally, Citigroup cut their price objective on GSK from GBX 2,250 to GBX 2,100 and set a "neutral" rating for the company in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of GBX 2,034.29. - Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging **Read Our Latest Research Report on GSK** ## About GSK (Get Free Report) GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. ## Featured Articles - Five stocks we like better than GSK - YETI Rallies After Earnings Beat and Raised Outlook - How the 3 Leading Quantum Firms Stack Up After Q1 Earnings - Cisco’s Vertical Rally May Still Be in the Early Innings - Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now _This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\]._ Insider Buying or Selling at GSK? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for GSK and related companies. From Our Partners SpaceX eyes a 1.75 trillion valuation - here's what to know Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a... Brownstone Research $30 stock to buy before Starlink goes public (WATCH NOW!) In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno... Paradigm Press Your book attached Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners... Profits Run My feud with Zohran Mamdani Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac... Stansberry Research Iran War Shock: What I Was Told In That Private Meeting You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th... Banyan Hill Publishing Why this tiny stock may move before the SpaceX IPO drops The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio... Behind the Markets Satellite Images Spot Potential $10 Trillion Discovery 'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a... Altimetry Read this or regret it forever Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P... Porter & Company ### Related Stocks - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [AKBA.US](https://longbridge.com/en/quote/AKBA.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [DB.US](https://longbridge.com/en/quote/DB.US.md) - [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [YETI.US](https://longbridge.com/en/quote/YETI.US.md) - [CSCO.US](https://longbridge.com/en/quote/CSCO.US.md) - [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md) - [BABA.US](https://longbridge.com/en/quote/BABA.US.md) - [09988.HK](https://longbridge.com/en/quote/09988.HK.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) - [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md) - [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [89988.HK](https://longbridge.com/en/quote/89988.HK.md) - [HBBD.SG](https://longbridge.com/en/quote/HBBD.SG.md) ## Related News & Research - [GSK Launches Final GBP 0.18 Bln Tranche Of GBP 2 Bln Share Buyback](https://longbridge.com/en/news/285899627.md) - [GSK: Japan's MHLW Expands Eligible Population For Arexvy](https://longbridge.com/en/news/286723820.md) - [GSK executives acquire shares under company reward plan](https://longbridge.com/en/news/286434027.md) - [GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks](https://longbridge.com/en/news/285980824.md) - [](https://longbridge.com/en/news/285955820.md)